Dr. Viraj Lavingia

Dr. Viraj Lavingia is a specialized gastrointestinal (GI) oncology expert with over 15 years of experience in the assessment and management of digestive system cancers. He has worked with some of India’s highest-regarded tertiary cancer care centers, including HCG Cancer Hospital in Ahmedabad between 2018-2023 where he also served as Director of the Department of GI Medical Oncology. Currently, he is the Head of the Department of Medical Oncology at Ahmedabad’s Shalby Hospitals, where he looks forward to leveraging his expertise to deliver outstanding investigative and therapeutic care for patients with digestive cancers.

Dr. Viraj Lavingia has organized a yearly GI oncology conference since 2018, which has facilitated key discussions between over 200 experts from across India regarding the latest developments in the GI malignancy care landscape to help raise national standards. He has served as principal investigator in over 15 major institutional and multi-center trials investigating various next-generation therapeutics for colorectal, gastric, and other GI tract tumors. He has co-authored over a dozen research papers in peer-reviewed medical journals focused on GI oncology. Dr. Lavingia has been actively involved in teaching and mentoring oncology trainees.

With his extensive and specialized expertise, Dr. Lavingia is exceptionally well-poised to deliver exemplary, holistic care for all types of digestive system and hepatobiliary cancers under Shalby Healthcare’s world-class tertiary oncology ecosystem.

• Apollo Hospital, Hyderabad – DNB Medical Oncology – 2017
• Breach Candy Hospital, Mumbai – DNB Internal Medicine – 2013
• Smt. NHL Municipal Medical College, Ahmedabad – MBBS – 2007

• Director GI Medical Oncology and Admin Head for Department of Medical Oncology, HCG Cancer Centre, Ahmedabad, April 2022 to September 2023
• Consultant Medical Oncologist (Gastrointestinal services), HCG Cancer Centre, Ahmedabad, May 2018 to March 2022
• Consultant Medical Oncologist, Apollo CBCC, Ahmedabad, November 2017 to May 2018
• DNB fellow, Apollo hospital, Hyderabad, July 2014 to June 2017
• Senior Registrar, Medical Oncology, Fortis, Mumbai, December 2013 to June 2014
• DNB scholar, Internal Medicine, Breach Candy Hospital, Mumbai, February 2009 to February 2012
• Medical Officer, Hemato-Oncology, Lilavati Hospital, Mumbai, June 2008- January 2009

• Dr. Viraj won a scholarship award (UICC fellowship from City of Hope, Duarte USA, June 2016) for the project “HAI (Hepatic Arterial Infusion) chemotherapy for liver-limited metastatic colorectal cancer”.

• ASCO
• ESMO
• NANETS
• IHPBA
• ISMPO
• IJMPO – associate editor for GI cancers

• GI Oncology
• Colorectal Cancers
• Pancreaticobiliary Cancers

• Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) – Results from the Multicentre Indian Pancreatic & Periampullary Adenocarcinoma Project (MIPPAP) Study – Journal of Gastrointestinal Oncology, June 2023 – doi: 10.1007/s12029-023-00936-1
• HER2 ‘neu’ promise for mCRC – Review article in International Journal of Molecular and Immuno Oncology, February 2023 – doi: 10.25259/IJMIO_30_2022
• Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2-overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study. SAGE Open Med Case Rep. 2022 Nov 27;10:2050313X221137447. doi: 10.1177/2050313X221137447
• Time for colorectal cancer screening in India! – Editorial in Indian Journal of Cancer, July 2021 – doi:10.4103/ijc.ijc_918_21
• Systemic Treatment for Metastatic Colorectal Cancer in the Era of Precision Medicine – Review article in Journal of Surgical Oncology, April 2019 – doi: 10.1002/jso.25421
• Impressive response to dual mutant intrahepatic cholangiocarcinoma – Journal of Gastrointestinal Oncology, December 2016 – doi: 10.21037/jgo.2016.09.13
• Pulmonary artery thrombosis mimicking disease progression in metastatic renal cell carcinoma while on sunitinib. Indian J Cancer 2016 – doi: 10.4103/0019-509X.180852
• PRES, the most uncommon side effect of one of the commonest chemotherapy regimen, FOLFOX. Apollo Medicine March 2015; doi: 10.1016/j.apme.2015.02.002